SP-420 Dosing Regimen With Recovery Intervals for Iron Overload

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current iron chelators for treating iron overload suffer from significant toxicity and non-compliance issues due to their dosing frequency and mechanism of action, leading to severe side effects, particularly in sensitive organs like the kidney and intestine.

Innovation Solution

A modified dosing regimen for the iron chelator SP-420, administered every other day or with weekend breaks, allows for cellular recovery periods, reducing the frequency of exposure to minimize toxicity while maintaining effective iron removal from the body.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If iron chelators are administered frequently to maintain effective iron removal, then iron clearance efficacy is improved, but toxicity to sensitive organs increases

Engineering Contradiction:
Improveiron clearance efficacyVSAvoidtoxicity to sensitive organs
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent implements periodic dosing regimens with drug-free intervals between treatment cycles. Patients receive iron chelation therapy for specific durations (e.g., 3-5 days) followed by drug-free periods (e.g., 2-7 days), creating a rhythmic pattern of treatment and recovery that allows sensitive organs to regenerate while maintaining overall iron clearance efficacy.

Inventive Principle:
Principle #19Periodic action

Solution Approach 2:

The patent applies preliminary protective measures before iron chelation therapy by administering protective agents or pre-conditioning treatments that shield sensitive organs from即将到来的 chelation stress. This preparatory action reduces organ vulnerability and enables higher effective dosing with reduced toxicity.

Inventive Principle:
Principle #10Preliminary action

2Productivity

If standard dosing regimens are used to ensure effective iron chelation, then iron removal is improved, but patient compliance deteriorates due to severe side effects

Engineering Contradiction:
Improveiron removal efficiencyVSAvoidpatient compliance
Core Design Contradiction:
ProductivityVSEase of operation

Solution Approach 1:

By structuring treatment as periodic cycles with drug-free intervals, the patent transforms continuous harsh dosing into manageable episodic treatment. This rhythmic approach allows patients to experience treatment benefits while having anticipated recovery periods, significantly improving adherence and reducing dropout rates.

Inventive Principle:
Principle #19Periodic action

Solution Approach 2:

The patent modifies dosing parameters including frequency, duration, and intensity of treatment cycles. By adjusting these parameters to create fluctuating dose patterns rather than constant dosing, the patent maintains therapeutic effectiveness while reducing cumulative toxicity and improving patient tolerance and compliance.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If continuous iron chelation therapy is administered to maximize iron clearance, then iron overload treatment is improved, but organ recovery time is reduced leading to cumulative damage

Engineering Contradiction:
Improveiron clearance rateVSAvoidorgan recovery duration
Core Design Contradiction:
ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent implements periodic dosing regimens with drug-free intervals between treatment cycles. Patients receive iron chelation therapy for specific durations (e.g., 3-5 days) followed by drug-free periods (e.g., 2-7 days), creating a rhythmic pattern of treatment and recovery that allows sensitive organs to regenerate while maintaining overall iron clearance efficacy.

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This regimen reduces the toxicity associated with iron chelation by allowing sensitive organs to recover from chelation effects, enhancing compliance and minimizing side effects without compromising overall iron clearance.

Implementation Method 1

iron chelators are small molecules that form complexes with iron and promote iron excretion

Methodology Applied
Scientific EffectChelation:

Data Source

PatentEP3493801B1Dosage regimens with (s)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in treating iron overload
Publication Date: 2025.12.31 ABFERO PHARMACEUTICALS INC
  • EP3493801B1 patent drawingFigure 1A
  • EP3493801B1 patent drawingFigure 1B
  • EP3493801B1 patent drawingFigure 2

AI summary

The present disclosure provides safe and effective dosing regimens of metal chelators as treatment for metal overload disorders and, in particular, iron overload and associated conditions.